Jim Simons
ATXI

Jim Simons’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Jim Simons’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-213
Closed -$19K – 4345
2023
Q1 		$19K Buy
+213
New +$19.7K ﹤0.01% 3835
2022
Q3 		– Sell
-111
Closed -$34K – 4489
2022
Q2 		$34K Buy
+111
New +$42.8K ﹤0.01% 4060
2021
Q4 		– Sell
-105
Closed -$176K – 4289
2021
Q3 		$176K Buy
105
+35
+50% +$72.3K ﹤0.01% 3231
2021
Q2 		$197K Buy
+70
New +$345K ﹤0.01% 3248
2020
Q4 		– Sell
-68
Closed -$822K – 3787
2020
Q3 		$822K Sell
68
-42
-38% -$510K ﹤0.01% 2605
2020
Q2 		$1.33M Buy
110
+51
+86% +$575K ﹤0.01% 2408
2020
Q1 		$597K Buy
59
+48
+436% +$481K ﹤0.01% 2669
2019
Q4 		$121K Buy
+11
New +$76.9K ﹤0.01% 3286
2019
Q3 		– Sell
-14
Closed -$101K – 3776
2019
Q2 		$101K Buy
14
+4
+40% +$23.2K ﹤0.01% 3397
2019
Q1 		$51K Buy
+10
New +$63.8K ﹤0.01% 3356

Other funds holding ATXI

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SAM
Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jim Simons's ATXI Position: Q2 2023 in Review

Jim Simons sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q2 2023, closing a stake of 213 shares — an estimated $19K sold.

Jim Simons first reported a position in ATXI in Q1 2019 and held it in 10 quarters. The position peaked at $1.33M in Q2 2020. 11 funds tracked by Wall St. Rank hold ATXI as of Q2 2023.

  • Jim Simons reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Jim Simons sold 213 Avenue Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $19K.
  • Jim Simons first reported a position in Avenue Therapeutics, Inc. Common Stock in Q1 2019 and held it in 10 quarters.
  • Jim Simons's Avenue Therapeutics, Inc. Common Stock position peaked at $1.33M in Q2 2020.
  • 11 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.